Quantum Biopharma Ltd (QNTM) Stock Price, Quote & News

Company Profile

Quantum BioPharma Ltd., together with its subsidiaries, operates as a biopharmaceutical company. The company operates through two segments, Biopharmaceutical Innovation and Strategic Investments. It researches and develops a portfolio of assets and biotech solutions for the treatment of neurodegenerative, inflammatory and metabolic disorders, and alcohol misuse disorders with drug candidates in different stages of development. The company's lead compound is Lucid-MS, a patented new chemical enti...

Industry: Biotechnology

Sector: Healthcare

Phone: 833 571 1811

Website: www.quantumbiopharma.com

Address:

1 Adelaide Street East, Suite 801, Toronto, Canada

NetworkNewsWire Sep. 17 at 3:34 PM

BioMedNewsBreaks — $QNTM Announces that Rodman & Renshaw Initiates Coverage with Buy Rating, $8 Price Target https://ibn.fm/WNsHM

0 · Reply

FickleFin Sep. 17 at 2:12 PM

$QNTM paid endorsement. Its the same recycled word vomit from the past few years. 🤡🤡🤡 Target 8 dollars? What happened to the 30+ dollars where it was at? Loser Malone is pumping this shit again. They used him for the pump and tossed him. Now he sits at their feet begging. What a chode. Guaranteed hes looking for exit liquidity.

1 · Reply

James23db Sep. 17 at 2:00 PM

$QNTM just bought 20 shares at 3.80, gonna dump now im sure. sorry boys and girls

1 · Reply

deedee12 Sep. 17 at 1:14 PM

$QNTM lots of fireworks when are the actual trials starting?

0 · Reply

deedee12 Sep. 17 at 1:10 PM

$QNTM There is nothing Quantum about Quantum Biopharma just the name!

0 · Reply

deedee12 Sep. 17 at 1:09 PM

$QNTM https://www.siskinds.com/context-is-everything-miller-v-fsd-pharma-inc/ 5 million dollar lawsuit

0 · Reply

deedee12 Sep. 17 at 1:07 PM

$QNTM https://www.newswire.ca/news-releases/fsd-pharma-adds-david-urban-to-board-of-directors-700453751.html the same David Urban who is part of Virtu Financial lol - https://ir.virtu.com/board-member/david-urban Algo trading

0 · Reply

deedee12 Sep. 17 at 1:04 PM

$QNTM who remembers this https://www.newswire.ca/news-releases/fsd-pharma-appoints-former-member-of-u-s-congress-to-its-board-of-directors-announces-share-consolidation-803600365.html

1 · Reply

deedee12 Sep. 17 at 1:03 PM

$QNTM So when are we starting the trials? Approval for trials doesn't mean they started it yet.

0 · Reply

rttr88 Sep. 17 at 1:01 AM

$QNTM I took a position today. Moves quickly with news.

1 · Reply

Rodman & Renshaw Initiates Analyst Coverage on Quantum BioPharma with a BUY Rating and US$8 Price Target

Sep 15, 2026, 8:00 AM EDT - 2 days ago

Quantum BioPharma to Attend the ArcStone-Kingswood Growth Summit 2026 in Toronto

Sep 14, 2026, 8:30 AM EDT - 3 days ago

NetworkNewsAudio Announces Audio Press Release (APR) Discussing FDA Clearance for Trial of First-in-Class Treatment Creating ‘Rare Moment' in MS Research

Sep 11, 2026, 8:30 AM EDT - 6 days ago

Quantum BioPharma Ltd. (NASDAQ: QNTM) Filling Key Gap in MS Treatment, Cleared by FDA to Launch Historic Trials

Sep 9, 2026, 8:30 AM EDT - 8 days ago

Quantum BioPharma Ltd. NASDAQ: QNTM) Receives FDA Clearance to Begin Trials for Historic MS Treatment

Sep 1, 2026, 7:00 PM EDT - 16 days ago

Quantum BioPharma Announces Plans to Voluntarily Delist its Class B Shares from the Canadian Securities Exchange

2026-08-31T11:10:12.000Z - 17 days ago

Quantum Group initiated with a Buy at Rodman & Renshaw

Aug 21, 2026, 7:00 PM EDT - 27 days ago

Quantum Biopharma Provides Corporate Update

Aug 14, 2026, 7:00 AM EDT - 4 weeks ago

Quantum BioPharma Strengthens Equity and Liquidity in Q2 2026 as FDA Approves Lucid-MS for Pivotal Phase 2 Clinical Trial

Aug 10, 2026, 7:00 AM EDT - 5 weeks ago

Quantum BioPharma Receives United States FDA Clearance To Proceed with Lucid-MS Phase 2 Trial in Progressive Multiple Sclerosis:

Jul 30, 2026, 12:18 AM EDT - 7 weeks ago

Quantum BioPharma Announces Closing of Debt Settlement

Jul 20, 2026, 7:00 PM EDT - 1 month ago

Quantum BioPharma Announces Intention to Settle Debt

Jul 7, 2026, 7:00 PM EDT - 2 months ago

Quantum BioPharma Provides Corporate Update

Jun 26, 2026, 8:30 AM EDT - 2 months ago

NetworkNewsAudio Announces Audio Press Release (APR) the Advancement of First-in-Class Treatment for Multiple Sclerosis

Jun 25, 2026, 8:30 AM EDT - 2 months ago

Quantum BioPharma Ltd. (NASDAQ: QNTM) Advancing Innovative, First-in-Class, Patented MS Therapy

Jun 23, 2026, 8:30 AM EDT - 2 months ago

Quantum BioPharma Ltd. (NASDAQ: QNTM) Developing Patented, First-in-Class MS Treatment That Offers Different Approach

Jun 2, 2026, 8:00 AM EDT - 3 months ago

IBN Announces Latest Episode of The BioMedWire Podcast Featuring Anthony Durkacz, Executive Co-Chair of Quantum BioPharma Ltd.

Jun 2, 2026, 7:40 AM EDT - 3 months ago

Quantum BioPharma Engages Stocks.news For Investor Relations, Marketing Services And Lead Generation Campaigns

May 18, 2026, 3:00 AM EDT - 4 months ago

Quantum BioPharma Reaches Key Midpoint Milestone in Groundbreaking Imaging Study with Massachusetts General Hospital

May 7, 2026, 7:00 AM EDT - 4 months ago

Quantum Reports Strengthened Liquidity, Reduced Cash Burn, and Disciplined Cost Management in First Quarter 2026

Apr 22, 2026, 9:16 AM EDT - 4 months ago

Quantum BioPharma Licensee Unbuzzd Wellness Inc. Appoints Richard Buzbuzian as CEO to Lead Nationwide Commercialization of Innovative, Clinically Validated Hangover Remedy and Alcohol Metabolism Accelerant

2026-04-01T12:25:14.000Z - 5 months ago

Quantum BioPharma submits Lucid-21-302 new drug application to the FDA

Apr 1, 2026, 8:02 AM EDT - 5 months ago

Quantum BioPharma Submits Investigational New Drug (IND) Application to United States Food and Drug Administration (FDA) for Lucid-MS Phase Two Clinical Trial in Multiple Sclerosis

2026-03-30T12:47:57.000Z - 5 months ago

Quantum BioPharma signs letter of intent with Allucent to conduct Lucid-MS trial

2026-03-30T12:28:19.000Z - 5 months ago

Quantum BioPharma signs letter of intent with Allucent to conduct Lucid-MS trial

Mar 30, 2026, 7:50 AM EDT - 5 months ago

Quantum BioPharma Signs Binding Letter Of Intent With Allucent To Conduct Phase 2 Clinical Trial In Multiple Sclerosis

Mar 27, 2026, 8:10 AM EDT - 5 months ago

Quantum Biopharma's 2025 Audited Year End Financial Results Maintain ‘No Going Concern' Status

Mar 23, 2026, 8:24 AM EDT - 5 months ago

Quantum BioPharma Announces Peer-Reviewed Journal Publication of Groundbreaking Clinical Trial With Unbuzzd

Mar 20, 2026, 7:35 PM EDT - 6 months ago

Quantum Biopharma Announces Closing of Initial Tranche of Private Placement Offering

Dec 23, 2025, 8:00 AM EST - 8 months ago

Quantum Biopharma Announces Completion of Dosing in 180-Day Repeated Dose Oral Toxicity and Toxicokinetic Studies for Lucid-21-302 (Lucid-MS)

Dec 10, 2025, 8:00 PM EST - 9 months ago

Quantum BioPharma Announces Closing of Private Placement & Provides Corporate Update

2025-12-01T12:15:18.000Z - 9 months ago

Quantum BioPharma announces airing of news segment on manipulation lawsuit

Nov 27, 2025, 4:00 PM EST - 9 months ago

Award-winning Investigative News Program W5 Airs Part 2 of 3-part Television Series on Alleged Stock Market Manipulation of Quantum Biopharma Involving Two of Canada's Largest Banks, CIBC and RBC

Nov 26, 2025, 9:30 AM EST - 9 months ago

Quantum Biopharma's USD $700 Million Lawsuit Alleging Stock Market Manipulation Subject of 3-part Series Investigative News Program W5

2025-11-07T12:12:42.000Z - 10 months ago

Quantum BioPharma reports Q3 EPS ($1.25) vs. (4.37) last year

2025-11-07T12:11:35.000Z - 10 months ago

Quantum BioPharma sees cash runway beyond March 2027

Nov 7, 2025, 7:00 AM EST - 10 months ago

Quantum Biopharma Reports Strong Third Quarter Results Maintaining ‘No Going Concern' Status with Cash Runway Extending Beyond March 2027, and $572,000 USD Gains in Crypto Portfolio

Oct 31, 2025, 7:51 PM EDT - 10 months ago

Quantum BioPharma Ltd. Provides Corporate Update

Oct 29, 2025, 9:00 PM EDT - 10 months ago

Quantum BioPharma Ltd. Announces Corporate Updates

Oct 23, 2025, 8:15 AM EDT - 10 months ago

Quantum BioPharma Licensee Unbuzzd Wellness to Host Live Webinar for its Disruptive Beverage Innovation that Speeds Alcohol Metabolism, Reduces Symptoms of Intoxication

2025-10-20T12:40:40.000Z - 11 months ago

Quantum BioPharma announces expiration of warrants held by hedge funds

Oct 20, 2025, 8:30 AM EDT - 11 months ago

Quantum BioPharma Ltd. Announces Expiration of All Warrants Held by Hedge Funds and Re-Iterates October 27, 2025, Record Date for the Distribution of a Special Dividend

Oct 9, 2025, 6:00 PM EDT - 11 months ago

Quantum BioPharma Ltd. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights – QNTM

Oct 8, 2025, 8:00 AM EDT - 11 months ago

Quantum BioPharma Announces Cash Reward of up to USD $7Million for Proof of Market Manipulation in its Stock

Oct 7, 2025, 11:00 AM EDT - 11 months ago

Quantum BioPharma: Engineering the Digital Balance Sheet in Life Sciences A Vanderbilt Report View

Oct 3, 2025, 7:00 AM EDT - 11 months ago

Quantum BioPharma Announces the Record Date for the Distribution of a Special Dividend of Contingent Value Rights (CVRs) Tied to the Future Litigation Settlement Proceeds of its USD $700 Million+ Case

Oct 2, 2025, 7:57 AM EDT - 11 months ago

Quantum BioPharma Receives Final Reports for Two Key Studies of its Potential Breakthrough Drug for Multiple Sclerosis, Moving Closer to Phase 2 Clinical Trial

Oct 1, 2025, 7:50 AM EDT - 11 months ago

Quantum BioPharma Welcomes World-Renowned Multiple Sclerosis Expert Dr. Jack Antel as Clinical Development Advisor For Lucid-MS Trials

Sep 29, 2025, 7:40 AM EDT - 11 months ago

Quantum BioPharma Ltd. Announces Results of Annual General and Special Meeting of Shareholders

Sep 26, 2025, 8:00 PM EDT - 11 months ago

Quantum BioPharma Announces Corporate Updates

Sep 24, 2025, 8:30 AM EDT - 11 months ago

Quantum BioPharma Licensee Unbuzzd Wellness to Host Live Webinar and Q&A Session on Wednesday, October 1, 2025

Sep 18, 2025, 8:10 AM EDT - 12 months ago

Health Canada Grants Quantum BioPharma a Product License for Its Innovative Product, Qlarity™, that Enhances Energy, and Promotes Metabolism, Mental Alertness and Cognitive Performance

Sep 12, 2025, 7:50 AM EDT - 1 year ago

Quantum BioPharma Licensee Unbuzzd Wellness to Host Investor Webinar on September 16, 2025 at 1:30 PM PT

Sep 10, 2025, 7:00 AM EDT - 1 year ago

Kingswood Capital Partners Initiates Analyst Coverage on Quantum BioPharma with a BUY Rating and US$45 Price Target

Aug 11, 2025, 6:32 PM EDT - 1 year ago

Quantum BioPharma Announces Update to Previously Announced Private Placement

Aug 11, 2025, 7:40 AM EDT - 1 year ago

Quantum BioPharma Signs Agreement to Manufacture Oral Drug Formulation of its Potential Breakthrough Drug Lucid-21-302 (Lucid-MS) for Use in its Upcoming Phase 2 Multiple Sclerosis Trial

NetworkNewsWire Sep. 17 at 3:34 PM

BioMedNewsBreaks — $QNTM Announces that Rodman & Renshaw Initiates Coverage with Buy Rating, $8 Price Target https://ibn.fm/WNsHM

0 · Reply

FickleFin Sep. 17 at 2:12 PM

1 · Reply

James23db Sep. 17 at 2:00 PM

$QNTM just bought 20 shares at 3.80, gonna dump now im sure. sorry boys and girls

1 · Reply

deedee12 Sep. 17 at 1:14 PM

$QNTM lots of fireworks when are the actual trials starting?

0 · Reply

deedee12 Sep. 17 at 1:10 PM

$QNTM There is nothing Quantum about Quantum Biopharma just the name!

0 · Reply

deedee12 Sep. 17 at 1:09 PM

$QNTM https://www.siskinds.com/context-is-everything-miller-v-fsd-pharma-inc/ 5 million dollar lawsuit

0 · Reply

deedee12 Sep. 17 at 1:07 PM

0 · Reply

deedee12 Sep. 17 at 1:04 PM

$QNTM who remembers this https://www.newswire.ca/news-releases/fsd-pharma-appoints-former-member-of-u-s-congress-to-its-board-of-directors-announces-share-consolidation-803600365.html

1 · Reply

deedee12 Sep. 17 at 1:03 PM

$QNTM So when are we starting the trials? Approval for trials doesn't mean they started it yet.

0 · Reply

rttr88 Sep. 17 at 1:01 AM

$QNTM I took a position today. Moves quickly with news.

1 · Reply

RollingPins Sep. 16 at 3:00 PM

$QNTM on the move today

0 · Reply

NetworkNewsWire Sep. 15 at 4:30 PM

QualityStocksNewsBreaks – $QNTM to Present at 3rd Annual ArcStone-Kingswood Growth Summit https://ibn.fm/7xOPw

0 · Reply

FickleFin Sep. 15 at 1:41 PM

$QNTM press release after press release after pump after 3rd party paid pumps... they are really trying hard to lure in stupid investors. So many red flags yet bagholders still hopeful. This is the PEA story all over again. (1st in class, hype words, 1st ever) look at all spamming all over X. Dont believe the hype. Why are they attending a summit in Toronto? It was delisted on the canadian exchange. Oh thats right. Loopholes.

2 · Reply

newsfile_corp Sep. 15 at 12:00 PM

https://nfne.ws/314327 $QNTM #Arcstone #CapitalMarkets #Growthsummit2026 #InvestmentBanking #NASDAQ #Investing

0 · Reply

Rambler1111 Sep. 14 at 6:33 PM

$QNTM

0 · Reply

LewisDaKat Sep. 14 at 6:30 PM

$QNTM NetworkNewsAudio Announces Audio Press Release (APR) Discussing FDA Clearance for Trial of First-in-Class Treatment Creating 'Rare Moment' in MS Research https://marketwirenews.com/stock/qntm/news/networknewsaudio-announces-audio-press-release-apr-d-8618913083084166.html?utm_source=stocktwits

0 · Reply

NetworkNewsWire Sep. 14 at 5:20 PM

NetworkNewsBreaks – $QNTM Featured in NetworkNewsAudio APR Highlighting FDA Clearance of Lucid-MS IND https://nnw.fm/E5nJp

0 · Reply

Invescent Sep. 14 at 5:54 AM

Low-cap catalyst watch for Monday $FFAI Float: ~ 3.85M Short: ~752K Short float: 19.5% Catalyst: Sept. 19 robotics launch — 9 new robot devices planned. Very tight float + high SI. $DPRO Public float used for latest SI calc: ~21.9M Short: ~3.76M Short float: 17.2% Catalyst: 5-year Canadian Armed Forces drone contract. 100 systems committed + option for 4,900 more (~C$24.25M option value). $QNTM Float: ~7.49M Short: ~261K Short float: 3.5% Catalyst: FDA clearance to advance Lucid-MS into Phase 2 for multiple sclerosis. $WHWK Float: ~28.6M Short: ~2.98M Short float: 10.4% Catalyst: New WCLC 2026 data supporting PTK7 as a target in lung cancer. Watching for volume Monday

0 · Reply

NetworkNewsWire Sep. 11 at 7:32 PM

InvestorNewsBreaks – $QNTM Featured in BioMedWire Editorial on Lucid-MS Phase 2 Trial https://ibn.fm/No4lN

0 · Reply

PrintingGains Sep. 11 at 6:39 PM

$QNTM wont sell at all

0 · Reply

FickleFin Sep. 11 at 5:43 PM

$QNTM 3yrs and still going... 🥴🥴🥴 Reason really why unbuzzd hasnt moved since inception. Never ending with the Continuance over and over. Safety $SHOT doesnt exist anymore and is now $BNKK 🥴🥴🥴 exit liquidity and loopholes

0 · Reply

focafoca99 Sep. 11 at 12:46 PM

$QNTM received FDA clearance to start a Phase 2 trial of its first-in-class MS drug Lucid-MS, a historic first for the mechanism.

0 · Reply

Market Cap	23.36M
Revenue (ttm)	0.00
Net Income (ttm)	-26.18M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	191,700
Avg Vol	196,364
Day's Range	N/A - N/A
Shares Out	6.40M
Stochastic %K	82%
Beta	0.45
Analysts	Strong Sell
Price Target	$21.75